Kazia Therapeutics Overview

  • Year Founded
  • 1994

Year Founded

  • Status
  • Public

  • Employees
  • 6

Employees

  • Stock Symbol
  • NV9

Stock Symbol

  • Investments
  • 4

Kazia Therapeutics General Information

Description

Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.

Contact Information

Website
www.kaziatx.com
Formerly Known As
Novogen, Norvet
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • Three International Towers
  • Level 24, 300 Barangaroo Avenue
  • Sydney, New South Wales 2000
  • Australia
+61 (02)
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Stock Exchange
ETR
Vertical(s)
Corporate Office
  • Three International Towers
  • Level 24, 300 Barangaroo Avenue
  • Sydney, New South Wales 2000
  • Australia
+61 (02)

Kazia Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Kazia Therapeutics Financials Summary

As of 31-Dec-2025, Kazia Therapeutics has a trailing 12-month revenue of $27.1K.

In Thousands,
USD
TTM 31-Dec-2025 FY 2025 30-Jun-2025 FY 2024 30-Jun-2024 FY 2023 30-Jun-2023
Revenue 27 27 1,513 0
EBITDA (15,861) (13,967) (16,509) (12,699)
Net Income (14,692) (13,395) (17,549) (13,758)
Total Assets 47,603 3,959 14,427 18,590
Total Debt 66 259 424 1,189
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Kazia Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Kazia Therapeutics‘s full profile, request access.

Request a free trial

Kazia Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company ha
Biotechnology
Sydney, Australia
6 As of 2025

Cambridge, MA
 

Boston, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Kazia Therapeutics Competitors (2)

One of Kazia Therapeutics’s 2 competitors is Blueprint Medicines, a Formerly VC-backed company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Blueprint Medicines Formerly VC-backed Cambridge, MA
Nimbus Therapeutics Venture Capital-Backed Boston, MA
You’re viewing 2 of 2 competitors. Get the full list »

Kazia Therapeutics Patents

Kazia Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2016901074-A0 Pharmaceutical compositions Inactive 22-Mar-2016
AU-2017201817-A1 Pharmaceutical compositions Inactive 22-Mar-2016
WO-2016187667-A1 Functionalised and substituted indoles as anti-cancer agents Inactive 27-May-2015
AU-2015291788-A1 Functionalised and substituted carbazoles as anti-cancer agents Inactive 16-Jul-2014
US-20170158636-A1 Functionalised and substituted carbazoles as anti-cancer agents Inactive 16-Jul-2014 C07D209/88
To view Kazia Therapeutics’s complete patent history, request access »

Kazia Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Kazia Therapeutics Investments & Acquisitions (4)

Kazia Therapeutics’s most recent deal was a Corporate Asset Purchase with QIMR Berghofer Medical Research Institute (Global Rights to the SETDB1 Platform) for . The deal was made on 13-Apr-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
QIMR Berghofer Medical Research Institute (Global Rights to the SETDB1 Platform) 13-Apr-2026 Corporate Asset Purchase Buildings and Property
Glioblast 31-Oct-2016 Merger/Acquisition Biotechnology
CanTx 06-Nov-2013 Joint Venture Drug Discovery
Triaxial Pharmaceuticals 05-Dec-2012 Merger/Acquisition Biotechnology
To view Kazia Therapeutics’s complete investments and acquisitions history, request access »

Kazia Therapeutics ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Pharmaceuticals

Subindustry

Rank

Percentile

To view Kazia Therapeutics’s complete esg history, request access »

Kazia Therapeutics Exits (1)

Kazia Therapeutics’s most recent exit was on 05-Dec-2012 from Triaxial Pharmaceuticals. The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
Triaxial Pharmaceuticals 05-Dec-2012 Completed
To view Kazia Therapeutics’s complete exits history, request access »

Kazia Therapeutics FAQs

  • When was Kazia Therapeutics founded?

    Kazia Therapeutics was founded in 1994.

  • Where is Kazia Therapeutics headquartered?

    Kazia Therapeutics is headquartered in Sydney, Australia.

  • What is the size of Kazia Therapeutics?

    Kazia Therapeutics has 6 total employees.

  • What industry is Kazia Therapeutics in?

    Kazia Therapeutics’s primary industry is Biotechnology.

  • Is Kazia Therapeutics a private or public company?

    Kazia Therapeutics is a Public company.

  • What is Kazia Therapeutics’s stock symbol?

    The ticker symbol for Kazia Therapeutics is NV9.

  • What is Kazia Therapeutics’s current revenue?

    The trailing twelve month revenue for Kazia Therapeutics is $27.1K.

  • Who are Kazia Therapeutics’s competitors?

    Blueprint Medicines and Nimbus Therapeutics are competitors of Kazia Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process